Merck & Co., Inc. Stock Forecast, Price & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRK stock has increased by 4.3% and is now trading at $82.69.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) announced its earnings results on Friday, July, 31st. The company reported $1.37 EPS for the quarter, beating the consensus estimate of $1.14 by $0.23. The company earned $10.87 billion during the quarter, compared to the consensus estimate of $10.52 billion. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The company's revenue was down 7.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.30 earnings per share.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Wednesday, July 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. declared that its Board of Directors has initiated a stock buyback program on Thursday, October 25th 2018, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 5.1% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

Merck & Co., Inc. issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

14 analysts have issued 12 month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $88.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $94.07 in the next year. This suggests a possible upside of 13.8% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

Headlines about MRK stock have been trending somewhat positive on Wednesday, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merck & Co., Inc. earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a decline in short interest in September. As of September 15th, there was short interest totaling 10,970,000 shares, a decline of 9.4% from the August 31st total of 12,110,000 shares. Based on an average trading volume of 7,950,000 shares, the short-interest ratio is currently 1.4 days. Currently, 0.4% of the shares of the company are short sold.
View Merck & Co., Inc.'s Short Interest.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $82.69.

Merck & Co., Inc. has a market capitalization of $209.14 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]